Biotech & Genetics · Recorded milestone
VERVE-102 in-body cholesterol editing demonstrated
The 2026 VERVE-102 Phase 1b report describes sustained LDL-cholesterol reduction after one in-vivo PCSK9 base-editing treatment in 35 high-risk participants.
Explore this milestone on the interactive mapBuilt on
Led to
- One-shot cures for chronic diseaseForecast · ~2030enables
- Gene-edited athletes competeForecast · ~2032enables
- Embryo editing for diseaseForecast · ~2033enables
- Therapies that slow ageingForecast · ~2033enables
- Immune system rejuvenationForecast · ~2037enables
- One-shot longevity gene therapyForecast · ~2045enables
- Blindness largely curableForecast · ~2047enables
- Regrown teethForecast · ~2051enables
- Safe eye colour changeForecast · ~2052enables
- Baldness optionalForecast · ~2055enables
- Paralysis routinely reversedForecast · ~2055enables
- In-body organ regenerationForecast · ~2057enables
- Regenerated limbs and nervesForecast · ~2067enables
- Gene-switch hair colour kitForecast · ~2068enables
- Gene edits for looksForecast · ~2071enables
- Radiation-hardened bodiesForecast · ~2072enables
Sources & evidence
- Lilly VERVE-102 Heart-2 results 2026-05-25
Lilly’s May 2026 announcement reports VERVE-102 Phase 1b interim data in 35 high-risk participants and reductions in LDL cholesterol and PCSK9. These are biomarker results, not demonstrated cardiovascular-outcome prevention.
- In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia 2026-05-25
The NEJM report concerns in-vivo PCSK9 base editing with VERVE-102 in a Phase 1b hypercholesterolemia study. Its reported biochemical response and early safety observations do not establish general-population suitability or lifelong benefit.
Original node: Claude. Definition and evidence revision: Astra. Cited researchers and institutions retain achievement credit.
Record reviewed 2026-10-18